The North America Uveitis Treatment Market is expected to witness market growth of 4.98% CAGR during the forecast period (2019-2025).
Iontophoresis is the use of electric current to help move molecules through the epithelium of the hydrophilic cornea, traditionally the greatest barrier to the penetration of medicines into the eye. It is expected to potentially increase the steroid medication's bioavailability, allowing for significantly reduced dosing frequency and improved effectiveness compared to topical corticosteroids. This procedure has the advantage of not being connected to many of the needle-related complications associated with many local procedures.
Treatment of post-infectious uveitis is a medical problem for ophthalmologists. The eye is a privileged site, preserved by blood ocular barriers that restrict the penetration of systemic antimicrobials into the corresponding segment. Furthermore, intraocularly, topical and subconjunctival treatments are unable to generate adequate concentrations of the medicines. Post-infectious uveitis can result from bacteria, viruses, fungi, or protozoa. The treatment method varies widely depending on the etiology of infections.
Based on Drug Class, the market is segmented into Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs and Other Drug Class. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online stores. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.
Scope of the Study
Market Segmentation:
By Drug Class
By Disease Type
By Distribution Channel
By Country
Companies Profiled
Unique Offerings from the Publisher
Iontophoresis is the use of electric current to help move molecules through the epithelium of the hydrophilic cornea, traditionally the greatest barrier to the penetration of medicines into the eye. It is expected to potentially increase the steroid medication's bioavailability, allowing for significantly reduced dosing frequency and improved effectiveness compared to topical corticosteroids. This procedure has the advantage of not being connected to many of the needle-related complications associated with many local procedures.
Treatment of post-infectious uveitis is a medical problem for ophthalmologists. The eye is a privileged site, preserved by blood ocular barriers that restrict the penetration of systemic antimicrobials into the corresponding segment. Furthermore, intraocularly, topical and subconjunctival treatments are unable to generate adequate concentrations of the medicines. Post-infectious uveitis can result from bacteria, viruses, fungi, or protozoa. The treatment method varies widely depending on the etiology of infections.
Based on Drug Class, the market is segmented into Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs and Other Drug Class. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online stores. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.
Scope of the Study
Market Segmentation:
By Drug Class
- Anti-inflammatory
- Immunotherapy & Targeted Therapies
- Antimicrobial Drugs
- Other Drug Class
By Disease Type
- Anterior Uveitis
- Posterior Uveitis
- Intermediate Uveitis
- Panuveitis
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online stores
By Country
- US
- Canada
- Mexico
- Rest of North America
Companies Profiled
- AbbVie, Inc.
- Alimera Sciences, Inc.
- Enzo Biochem, Inc.
- Amgen, Inc.
- Bausch Health Companies, Inc.
- Clearside Biomedical, Inc.
- EyePoint Pharmaceuticals, Inc.
- Santen Pharmaceutical Co., Ltd.
- TopiVert Ltd.
- Novartis AG
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Uveitis Treatment Market by Drug Class
Chapter 4. North America Uveitis Treatment Market by Disease Type
Chapter 5. North America Uveitis Treatment Market by Distribution Channel
Chapter 6. North America Uveitis Treatment Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- AbbVie, Inc.
- Alimera Sciences, Inc.
- Enzo Biochem, Inc.
- Amgen, Inc.
- Bausch Health Companies, Inc.
- Clearside Biomedical, Inc.
- EyePoint Pharmaceuticals, Inc.
- Santen Pharmaceutical Co., Ltd.
- TopiVert Ltd.
- Novartis AG
Methodology
LOADING...
